Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Abstract highlighting new preclinical data from LP-50 in non-muscle invasive bladder cancer PITTSBURGH, Pa., May 29, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces an abstract publication at the 2024 American Society of Clinical O ...

Company to initiate Phase 2b clinical trial in lead asset, LP-10 in 2H 2024 Pittsburgh, PA, May 21, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company, announced today the receipt of U.S. Food & Drug Administration ("FDA") Type-C meeting guidance regarding the LP-10 (liposomal tacrolimus) clinical program. Lipella expects to initiate a Phase 2b clinical trial evaluating LP-10 as a treatment for hemorrhagic cystitis in approximately 36 pati ...

PITTSBURGH, May 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company, announced today the receipt of U.S. Food & Drug Administration ("FDA") Type-C meeting guidance regarding the LP-10 (liposomal tacrolimus) clinical program. Lipella expects to initiate a Phase 2b clinical trial evaluating LP-10 as a treatment for hemorrhagic cystitis in approximately 36 patients in the second half of 2024. The FDA provided preliminary a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41575 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of inco ...

PITTSBURGH, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company, today announced the expansion of its Scientific Advisory Board to include oncology expertise. The new committee members are: Jason Hafron, MD, DDS, PhD, MPH, the Chief Medical Officer at Michigan Institute of Urology, and Professor of Urology at the William Beaumont School of Medicine; and Pradeep Tyagi, PhD, MBA, Professor of Urology, Universit ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 001-41575 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) (State or other ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41575 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) | Delaware | 20-2388040 | | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41575 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 20-2388040 (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41575 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) | Delaware | 20-2388040 | | --- | - ...

Product Development and Clinical Trials - The company is developing LP-10 for the treatment of hemorrhagic cystitis (HC), a condition affecting approximately 72,000 patients annually in the U.S. due to radiation therapy and 60,000 patients from systemic chemotherapy[32]. - A phase 2a clinical trial for LP-10 commenced on February 15, 2021, with top-line results reported in January 2023 indicating proof-of-concept in humans[23][32]. - The phase 2a clinical trial for LP-10 involved 13 subjects, with a median age of 67 years, and demonstrated a complete response in 3 subjects and a partial response in 7 subjects[61]. - The phase 2a trial for LP-10 reported no related adverse events or elevated blood tacrolimus levels, indicating good tolerability[61]. - The company concluded phase 2a clinical trials for LP-10, demonstrating no serious adverse events and improved urinary symptoms, with full results expected in Q2 2023[111]. - LP-310 is currently in pre-clinical development, targeting a chronic immune-mediated mucosal disease affecting over 6 million people in the U.S. and Europe[65]. Regulatory Approvals and Designations - The company received FDA "orphan drug" designation for LP-10, which is expected to expedite the regulatory approval process[22]. - The FDA granted IND approval for LP-10 on December 23, 2019, allowing for a phase 2a clinical trial to be conducted at eight clinical sites[34]. - The company intends to apply for FDA accelerated approval pathways, including Breakthrough Therapy designation, for LP-10[34]. - The company plans to submit a new request for Fast Track designation for LP-10 following the reporting of phase 2a clinical trial summary results in January 2023[96]. - The initial request for Fast Track designation for LP-10 was denied by the FDA in September 2021[96]. - The company plans to submit a marketing authorization application to the EMA for LP-10, but the process is lengthy and costly[156]. - The company intends to pursue the 505(b)(2) regulatory pathway for LP-10, but there is no guarantee that this pathway will be available[164]. Market Opportunity and Financial Projections - LP-10 is projected to have a price exceeding $20,000 per patient-year, with potential annual gross revenue of up to $1.2 billion based on a 50% market penetration[52]. - Approximately 72,000 cancer survivors experience severe chronic bladder bleeding annually, with an additional 60,000 patients suffering from chemotherapy-related cystitis, indicating an addressable market exceeding 120,000 patients[49]. - The company estimates that the peak demand for LP-10 could be approximately 60,000 patients annually in the U.S.[52]. - LP-310 is projected to cost approximately $4,000 annually per patient, resulting in a total addressable market exceeding $980 million for the treatment of OLP[70]. Competitive Landscape and Intellectual Property - The proprietary platform technology is protected by patents in the U.S., Australia, and Canada, with additional applications pending in the U.S. and Europe[26]. - The company has received U.S. patent number 10,639,278, which expires on July 11, 2035, and U.S. patent number 11,357,725, expiring on November 9, 2034, covering aspects of its Platform technology[81]. - The company intends to rely on FDA "orphan drug" designation and issued patents to maintain competitive advantages in the biotechnology space[105]. - The company faces significant competition in the biotechnology sector, with competitors potentially achieving regulatory approval faster[172]. - The company faces risks related to patent expirations, which could increase competition and limit demand for its product candidates[173]. Financial Condition and Funding Needs - As of December 31, 2022, the company had an accumulated deficit of approximately $5.7 million, with a net loss of about $2.6 million for the year[121]. - The company has incurred net losses since inception and expects to continue incurring losses for the foreseeable future[120]. - The company will need to raise additional funding to receive approval for LP-10 and to build the necessary sales and marketing infrastructure[124]. - The company may require additional financing to achieve its business objectives, which could dilute existing stockholders' holdings[127]. Manufacturing and Compliance - The facility includes approximately 2,000 square feet of space with cGMP-capable manufacturing capabilities[72]. - The company is continuously enhancing its manufacturing compliance to meet increasing regulatory requirements as LP-10 progresses through clinical trials[75]. - Manufacturing processes for product candidates, including LP-10, are complex and may face delays due to regulatory approvals and compliance with cGMP standards[174]. - The company may need to rely on third-party manufacturers, which poses risks if they fail to meet contractual obligations or regulatory requirements[176]. Risks and Challenges - The company may face significant delays or inability to commercialize LP-10 if it does not achieve timely regulatory approvals[132]. - The company is currently supported by government grant awards, which may be reduced or eliminated in the future, impacting research funding[128]. - The uncertainty of third-party coverage and reimbursement for newly approved products may limit the company's ability to generate product revenue[186]. - Legislative reforms in healthcare could materially affect the company's ability to market and profit from its product candidates[192]. - The ongoing COVID-19 pandemic may disrupt clinical trial operations and patient recruitment, adversely affecting the company's ability to obtain regulatory approvals[213]. - Unfavorable global economic conditions, including inflation and supply chain disruptions, could negatively impact the company's financial condition and operations[214]. Employee and Operational Considerations - The company has five full-time employees and two part-time employees as of March 27, 2023[106]. - Retaining key employees and scientific advisors is critical for the company's success, as their loss could materially impact business operations and objectives[203]. - The company does not currently hold key man insurance for its executives, which could pose risks if key personnel leave[204]. Legal and Compliance Issues - The company is subject to rigorous FDA regulations post-approval, including compliance with cGMP requirements[101]. - The company may face substantial penalties if unable to comply with federal and state healthcare fraud and abuse laws, including the federal Anti-Kickback Statute and false claims laws[197]. - Compliance with healthcare laws and regulations will involve significant costs, and violations could lead to civil, criminal, and administrative penalties, including exclusion from government healthcare programs[200]. - The company is at risk of being found in violation of various laws due to their broad interpretations and the complexity of compliance across multiple jurisdictions[201].